The Menopausal Transition: the Hormonal Milieu

Total Page:16

File Type:pdf, Size:1020Kb

The Menopausal Transition: the Hormonal Milieu Physiology of the Menopausal Transition: The Hormonal Milieu Nanette Santoro, MD Professor and E Stewart Taylor Chair of Obstetrics and Gynecology University of Colorado School of Medicine Advisory Board and Stock Options: Menogenix, Inc Consultant: Ansh Laboratories, Astellas/Ogeda Disclosures Learning Objectives At the conclusion of this lecture, the listener is expected to: Enumerate the patterns of hormones and symptoms that occur during the menopause transition Apply this information to anticipate how hormone changes may relate to symptoms STRAW Stages of Reproductive Aging Surrounding the MT -3b/-3a Late -2b -2a Late Peri +1a/1b Reproductive: Early Peri Cycles >=60 days Menses have ended Cycles regular/slightly apart irregular Cycles variable* FSH high FSH high Normal to variable FSH Variable FSH Ovarian reserve very Ovarian reserve low low to undetectable Ovarian reserve low Ovarian reserve low *Early perimenopausal cycles may be defined as either >7 days difference in cycle length or duration of amenorrhea <60 days. Adapted from Harlow,et al: Menopause 2012; 19: The Road to Menopause Pre-MT Early MT Late MT Menses • reserve 3-11 Regular Normal Skipped •>1 Prolonged mos ovarian cycles period/3 Amenorrhea reserve mos apart Median Age 47 Median Age 49 Early Transition Low ovarian reserve results in: Lowered AMH Lowered inhibin B and A (luteal phase) Intermittent increases in FSH Erratic hormone patterns The MT is the Tipping Point for Disruption of Negative Feedback Loops Estradiol Negative producing feedback upon FSH Preovulatory FSH dependent follicle Inhibin producing Antral follicles AMH producing Pre-antral follicles FSH independent Primordial follicles (true ovarian reserve) Probable Sequence of Events Lowered ovarian reserve (clinically silent), leads to: Less AMH, inhibin B and inhibin A, which leads to: Less restraint on FSH, which leads to: ’Rapid’ cycles, short follicular phases, and follicle maturation that begins before the next menses Estradiol feedback may be of lesser importance at this time in the transition E2 and Inhibin Changes in Relation to FMP Burger, H. G. et al. J Clin Endocrinol Metab 1999;84:4025-4030 Copyright ©1999 The Endocrine Society LOOP (Luteal Out Of Phase) Cycles ©2009The North American Menopause Society. Published by Lippincott Williams & Wilkins, Inc. 2 Hale, Georgina; Menopause. 16(1):50-59, January 2009. Transition Hormone Patterns Individual Perimenopausal Woman The Net Result of Early MT Changes More frequent menses Longer luteal phases relative to follicular phase (prolonged PMDD) Wider hormone excursions that in midreproductive life= Worse migraines Greater ‘menstrual magnification’ of pre-existing conditions that were tolerable in mid-reproductive life Late MT 60-364 days of amenorrhea More prolonged stretches of low estradiol, failure to produce progesterone Hot spot for acceleration of ‘typical’ menopausal symptoms (hot flashes, vaginal dryness, adverse mood, sleep changes) Predicted Menstrual Cycle Length By Luteal Activity ELA cycles=solid lines non-ELA cycles=dashed lines The Journal of Clinical Endocrinology & Metabolism, Volume 102, Issue 7, 1 July 2017, Pages 2218– 2229, https://doi.org/10.1210/jc.2016-4017 The content of this slide may be subject to copyright: please see the slide notes for details. Whole Cycle Hormones by Cycle Type The Journal of Clinical Endocrinology & Metabolism, Volume 102, Issue 7, 1 July 2017, Pages 2218–2229, https://doi.org/10.1210/jc.2016-4017 The content of this slide may be subject to copyright: please see the slide notes for details. Ovulatory Type Cycles Get Rarer— But Only Towards the End of the Transition From: Menstrual Cycle Hormone Changes in Women Traversing Menopause: Study of Women’s Health Across the Nation J Clin Endocrinol Metab. 2017;102(7):2218-2229. doi:10.1210/jc.2016-4017 J Clin Endocrinol Metab | Copyright © 2017 Endocrine Society What We Have Learned Hormone patterns don’t really become ‘estrogen deficient’ until the late transition Instability of overall day-to-day and month-to-month patterns may cause symptoms starting in the early transition Earlier onset of the MT = a longer, more symptomatic process Paramsothy P, Menopause 2017; 24: 142 Can we use a blood test to predict menopause? Antimullerian hormone (AMH) produced by granulosa cells of primary and growing follicles Provides a direct measurement of ovarian reserve If sufficiently sensitive, should theoretically predict the time to menopause (FMP) Cross Sectional AMH in Women Aged 24-50 Seifer D, Fertil Steril 2011; 95: 747 SWAN AMH Project • Pre- or early perimenopausal and age 42- 52 when enrolled in SWAN • At least 1 blood sample available while pre- or early perimenopausal for initial AMH • AMH measured annually until 12 months after the FMP Results • AMH was measured on 7714 blood samples from 1536 women (average 5 samples/woman) • African-American – 2177 samples • Caucasian – 3494 samples • Chinese -- 781 samples • Japanese --975 samples • Hispanic – 287 samples Mean age at time of 1st AMH measurement = 47.5 Serum AMH vs Time to FMP What we learned A sensitive and specific AMH assay CAN predict time to menopause…and can also predict when imminent menopause is unlikely Clinical Lessons Learned from SWAN Why do migraine headaches worsen during the menopausal transition? Pavlovic J, Neurology 2016; 87:49 Luteal Estrogen Declines More Rapidly in Perimenopausal Migraineurs Clinical Lessons Learned from SWAN When do women lose bone density in association with menopause? Are we screening the right people at the right time? What We Thought We Knew Bone loss begins in the late 40’s/early 50’s It’s associated with menopause, somehow… Bone Loss Is Not Evident Until the Late MT Finkelstein JCEM 2008; 93: 861 Lumbar Spine BMD Loss in Relation to FMP Greendale J Bone Miner Res 2012; 27: 111 A New Model For Bone Loss Emerges Shieh, A, Clin NA Ob Gyn 2018 Summary The menopause transition is NOT a gradual process of hormone withdrawal Initial loss of negative feedback restraint on the HPO axis causes acceleration of folliculogenesis, asynchronous cycles, and destabilizing hormone fluctuations for some Later transition changes more closely mimic those associated with classic estrogen deficiency models Clinicians need to appreciate how these differing phases of the transition will influence the symptom experience for women.
Recommended publications
  • Dental Considerations in Pregnancy and Menopause
    J Clin Exp Dent. 2011;3(2):e135-44. Pregnancy and menopause in dentistry. Journal section: Oral Medicine and Pathology doi:10.4317/jced.3.e135 Publication Types: Review Dental considerations in pregnancy and menopause Begonya Chaveli López, Mª Gracia Sarrión Pérez, Yolanda Jiménez Soriano Valencia University Medical and Dental School. Valencia (Spain) Correspondence: Apdo. de correos 24 46740 - Carcaixent (Valencia ), Spain E-mail: [email protected] Received: 01/07/2010 Accepted: 05/01/2011 Chaveli López B, Sarrión Pérez MG, Jiménez Soriano Y. Dental conside- rations in pregnancy and menopause. J Clin Exp Dent. 2011;3(2):e135-44. http://www.medicinaoral.com/odo/volumenes/v3i2/jcedv3i2p135.pdf Article Number: 50348 http://www.medicinaoral.com/odo/indice.htm © Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488 eMail: [email protected] Abstract The present study offers a literature review of the main oral complications observed in women during pregnancy and menopause, and describes the different dental management protocols used during these periods and during lac- tation, according to the scientific literature. To this effect, a PubMed-Medline search was made, using the following key word combinations: “pregnant and dentistry”, “lactation and dentistry”, “postmenopausal and dentistry”, “me- nopausal and dentistry” and “oral bisphosphonates and dentistry”. The search was limited to reviews, metaanalyses and clinical guides in dental journals published over the last 10 years in English and Spanish. A total of 38 publi- cations were evaluated. Pregnancy can be characterized by an increased prevalence of caries and dental erosions, worsening of pre-existing gingivitis, or the appearance of pyogenic granulomas, among other problems.
    [Show full text]
  • 6 Ways Your Brain Transforms During Menopause
    6 Ways Your Brain Transforms During Menopause By Aviva Patz Movies and TV shows have gotten a lot of laughs out of menopause, with its dramatic hot flashes and night sweats. But the midlife transition out of our reproductive years—marked by yo-yoing of hormones, mostly estrogen—is a serious quality-of-life issue for many women, and as we're now learning, may leave permanent marks on our health. "There is a critical window hypothesis in that what is done to treat the symptoms and risk factors during perimenopause predicts future health and symptoms," explains Diana Bitner, MD, assistant professor at Michigan State University College of Human Medicine and author of I Want to Age Like That: Healthy Aging Through Midlife and Menopause. "If women act on the mood changes in perimenopause and get healthy and take estrogen, the symptoms are much better immediately and also lifelong." (Going through menopause and your hormones are out of whack? Then check out The Hormone Reset Diet to balance your hormones and lose weight.) For many decades, the mantra has been that the only true menopausal symptoms are hot flashes and vaginal dryness. Certainly they're the easiest signs to spot! But we have estrogen receptors throughout the brain and body, so when estrogen levels change, we experience the repercussions all over—especially when it comes to how we think and feel. Two large studies, including one of the nation's longest longitudinal investigations, have revealed that there's a lot going on in the brain during this transition. "Before it was hard to tease out: How much of this is due to the ovaries aging and how much is due to the whole body aging?" says Pauline Maki, PhD, professor of psychiatry and psychology at the University of Illinois at Chicago and Immediate Past President of the North American Menopause Society (NAMS).
    [Show full text]
  • Luteal Phase Deficiency: What We Now Know
    ■ OBGMANAGEMENT BY LAWRENCE ENGMAN, MD, and ANTHONY A. LUCIANO, MD Luteal phase deficiency: What we now know Disagreement about the cause, true incidence, and diagnostic criteria of this condition makes evaluation and management difficult. Here, 2 physicians dissect the data and offer an algorithm of assessment and treatment. espite scanty and controversial sup- difficult to definitively diagnose the deficien- porting evidence, evaluation of cy or determine its incidence. Further, while Dpatients with infertility or recurrent reasonable consensus exists that endometrial pregnancy loss for possible luteal phase defi- biopsy is the most reliable diagnostic tool, ciency (LPD) is firmly established in clinical concerns remain about its timing, repetition, practice. In this article, we examine the data and interpretation. and offer our perspective on the role of LPD in assessing and managing couples with A defect of corpus luteum reproductive disorders (FIGURE 1). progesterone output? PD is defined as endometrial histology Many areas of controversy Linconsistent with the chronological date of lthough observational and retrospective the menstrual cycle, based on the woman’s Astudies have reported a higher incidence of LPD in women with infertility and recurrent KEY POINTS 1-4 pregnancy losses than in fertile controls, no ■ Luteal phase deficiency (LPD), defined as prospective study has confirmed these find- endometrial histology inconsistent with the ings. Furthermore, studies have failed to con- chronological date of the menstrual cycle, may be firm the superiority of any particular therapy. caused by deficient progesterone secretion from the corpus luteum or failure of the endometrium Once considered an important cause of to respond appropriately to ovarian steroids.
    [Show full text]
  • Relation of Cardiovascular Risk Factors in Women Approaching Menopause
    University of Massachusetts Medical School eScholarship@UMMS Women’s Health Research Faculty Publications Women's Faculty Committee 2006-02-24 Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive hormones in the follicular and luteal phases Karen A. Matthews Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/wfc_pp Part of the Cardiology Commons, Obstetrics and Gynecology Commons, and the Preventive Medicine Commons Repository Citation Matthews KA, Santoro N, Lasley WL, Chang Y, Crawford SL, Pasternak RC, Sutton-Tyrrell K, Sowers M. (2006). Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive hormones in the follicular and luteal phases. Women’s Health Research Faculty Publications. https://doi.org/10.1210/jc.2005-1057. Retrieved from https://escholarship.umassmed.edu/wfc_pp/43 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Women’s Health Research Faculty Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Cardiovascular Risk Factors 1 Are the Cardiovascular Risk Factors of Women Approaching Menopause associated with Menstrual Cycle Characteristics and Reproductive Hormones in the Follicular and Luteal Phase?: Study of Women’s Health Across the Nation Daily Hormone Study Karen A. Matthews, PhD. 1 Nanette Santoro, MD 2, Bill Lasley, PhD. 3, Yuefang Chang, PhD. 4, Sybil Crawford, PhD. 5, Richard C. Pasternak, MD 6, Kim Sutton-Tyrrell, DrPH 4, and Mary Fran Sowers, PhD. 7 1 Departments of Psychiatry, Epidemiology and Psychology, University of Pittsburgh, Pittsburgh, PA.
    [Show full text]
  • Endocrine Control of Lactational Infertility. I
    Maternal Nutrition and Lactational Infertility, edited by I. Dobbing. Nestld Nutrition, Vevey/ Raven Press, New York © 1985. Endocrine Control of Lactational Infertility. I *Alan S. McNeilly, *Anna Glasier, and fPeter W. Howie *MRC Reproductive Biology Unit, Edinburgh EH3 9EW, and 1'Department of Obstetrics and Gynaecology, University of Dundee Medical School, Ninewells Hospital, Dundee DD1 951, Scotland Although there is no doubt that breastfeeding suppresses ovarian activity, the reasons for the immense variability in the duration of this suppression and the mechanisms by which the suckling stimulus causes it remain unclear. The interbirth interval in women who breastfeed can be divided into three main components: (a) the period of lactational amenorrhoea, (b) a period when menstruation returns either during or after lactation, and (c) pregnancy. The length of periods a and b will vary considerably depending on the pattern of breastfeeding, and in a few cases pregnancy will occur during the period of lactational amenorrhoea without an intervening period of menstrual cycles. In an attempt to clarify the mechanisms controlling each of periods a and b above, the changes in endocrine and ovarian activities will be explored. GONADOTROPHIC CONTROL OF THE MENSTRUAL CYCLE Before discussing in detail the influences of suckling on ovarian activity, it is first necessary to outline the basic mechanisms controlling the growth and devel- opment of follicles and subsequent formation of the corpus luteum in the normal menstrual cycle. The basic changes in the four principal hormones involved are shown in Fig. 1. At the time of menses following the demise of the corpus luteum of the previous cycle, follicle development starts, and usually a single follicle begins to grow.
    [Show full text]
  • Variability in the Length of Menstrual Cycles Within and Between Women - a Review of the Evidence Key Points
    Variability in the Length of Menstrual Cycles Within and Between Women - A Review of the Evidence Key Points • Mean cycle length ranges from 27.3 to 30.1 days between ages 20 and 40 years, follicular phase length is 13-15 days, and luteal phase length is less variable and averages 13-14 days1-3 • Menstrual cycle lengths vary most widely just after menarche and just before menopause primarily as cycles are anovulatory 1 • Mean length of follicular phase declines with age3,11 while luteal phase remains constant to menopause8 • The variability in menstrual cycle length is attributable to follicular phase length1,11 Introduction Follicular and luteal phase lengths Menstrual cycles are the re-occurring physiological – variability of menstrual cycle changes that happen in women of reproductive age. Menstrual cycles are counted from the first day of attributable to follicular phase menstrual flow and last until the day before the next onset of menses. It is generally assumed that the menstrual cycle lasts for 28 days, and this assumption Key Points is typically applied when dating pregnancy. However, there is variability between and within women with regard to the length of the menstrual cycle throughout • Follicular phase length averages 1,11,12 life. A woman who experiences variations of less than 8 13-15 days days between her longest and shortest cycle is considered normal. Irregular cycles are generally • Luteal phase length averages defined as having 8 to 20 days variation in length of 13-14 days1-3 cycle, whereas over 21 days variation in total cycle length is considered very irregular.
    [Show full text]
  • Infertility Investigations for Women
    Infertility investigations for women Brooke Building Gynaecology Department 0161 206 5224 © G21031001W. Design Services, Salford Royal NHS Foundation Trust, All Rights Reserved 2021. Document for issue as handout. Unique Identifier: SURG08(21). Review date: May 2023. This booklet is aimed for women undergoing fertility LH (Luteinising Hormone) Progesterone investigations. Its’ aim is to Oligomenorrhoea - When the provide you with some useful periods are occurring three In women, luteinising hormone Progesterone is a female information regarding your or four times a year (LH) is linked to ovarian hormone produced by the hormone production and egg ovaries after ovulation. It investigations. Irregular cycle - Periods that maturation. LH is used to causes the endometrial lining vary in length We hope you !nd this booklet measure a woman’s ovarian of the uterus to get thicker, helpful. The following blood tests are reserve (egg supply). making it receptive for a used to investigate whether You will be advised to have some It causes the follicles to grow, fertilised egg. ovulation (production of an egg) or all of the following tests: mature and release the eggs Progesterone levels increase is occurring each month and also for fertilisation. It reaches its after ovulation, reaching a to help determine which fertility Hormone blood tests highest level (the LH surge) in maximum level seven days treatments to offer. Follicular bloods tests the middle of the menstrual before the start of the next cycle 48 hours prior to ovulation period. The progesterone test is These routine blood tests are FSH (Follicle Stimulating i.e. days 12-14 of a 28 day cycle.
    [Show full text]
  • The Evolutionary Ecology of Age at Natural Menopause
    1 The Evolutionary Ecology of Age at Natural 2 Menopause: Implications for Public Health 3 4 Abigail Fraser1,3, Cathy Johnman1, Elise Whitley1, Alexandra Alvergne2,3,4 5 6 7 1 Institute of Health and Wellbeing, University of Glasgow, UK 8 2 ISEM, Université de Montpellier, CNRS, IRD, EPHE, Montpellier, France 9 3 School of Anthropology & Museum Ethnography, University of Oxford, UK 10 4 Harris Manchester College, University of Oxford, UK 11 12 13 14 15 16 17 18 19 Author for correspondence: 20 [email protected] 21 22 23 Word count: 24 Illustrations: 2 boxes; 3 figures; 1 table 25 26 27 Key words: reproductive cessation, life-history, biocultural, somatic ageing, age at 28 menopause, ovarian ageing. 29 1 30 31 Abstract 32 33 Evolutionary perspectives on menopause have focused on explaining why early 34 reproductive cessation in females has emerged and why it is rare throughout the 35 animal kingdom, but less attention has been given to exploring patterns of diversity in 36 age at natural menopause. In this paper, we aim to generate new hypotheses for 37 understanding human patterns of diversity in this trait, defined as age at final menstrual 38 period. To do so, we develop a multi-level, inter-disciplinary framework, combining 39 proximate, physiological understandings of ovarian ageing with ultimate, evolutionary 40 perspectives on ageing. We begin by reviewing known patterns of diversity in age at 41 natural menopause in humans, and highlight issues in how menopause is currently 42 defined and measured. Second, we consider together ultimate explanations of 43 menopause timing and proximate understandings of ovarian ageing.
    [Show full text]
  • Trends and Patterns in Menarche in the United States: 1995 Through 2013–2017 by Gladys M
    National Health Statistics Reports Number 146 September 10, 2020 Trends and Patterns in Menarche in the United States: 1995 through 2013–2017 By Gladys M. Martinez, Ph.D. Abstract older, have older friends, and be more likely to engage in negative behaviors Objective—This report presents national estimates of age at first menstrual period such as missing school, smoking, and for women aged 15–44 in the United States in 2013–2017 based on data from the drinking (8–11). The younger the age at National Survey of Family Growth (NSFG). Estimates for 2013–2017 are compared first menstrual period and first sexual with those from previous NSFG survey periods (1995, 2002, and 2006–2010). intercourse, the longer the interval Methods—Data for all survey periods analyzed are based on in-person interviews young women will potentially spend at with nationally representative samples of women in the household population aged risk of pregnancy. Differences in age at 15–44 in the United States. For the 2013–2017 survey period, interviews were menarche across population subgroups conducted with 10,590 female respondents aged 15–44. In 2015–2017, the age range may help explain differences in timing of the NSFG included women aged 15–49, but only those aged 15–44 were included of first sexual intercourse and timing of in this analysis. The response rate for the 2013–2017 NSFG was 67.4% for women. first births. The relationship between age Measures of menarche in this report include average age at first menstrual period, at menarche and the timing of first sexual probability of first menstrual period at each age, and the relationship between age at intercourse in the United States has menarche and age at first sexual intercourse.
    [Show full text]
  • Changes Before the Change1.06 MB
    Changes before the Change Perimenopausal bleeding Although some women may abruptly stop having periods leading up to the menopause, many will notice changes in patterns and irregular bleeding. Whilst this can be a natural phase in your life, it may be important to see your healthcare professional to rule out other health conditions if other worrying symptoms occur. For further information visit www.imsociety.org International Menopause Society, PO Box 751, Cornwall TR2 4WD Tel: +44 01726 884 221 Email: [email protected] Changes before the Change Perimenopausal bleeding What is menopause? Strictly defined, menopause is the last menstrual period. It defines the end of a woman’s reproductive years as her ovaries run out of eggs. Now the cells in the ovary are producing less and less hormones and menstruation eventually stops. What is perimenopause? On average, the perimenopause can last one to four years. It is the period of time preceding and just after the menopause itself. In industrialized countries, the median age of onset of the perimenopause is 47.5 years. However, this is highly variable. It is important to note that menopause itself occurs on average at age 51 and can occur between ages 45 to 55. Actually the time to one’s last menstrual period is defined as the perimenopausal transition. Often the transition can even last longer, five to seven years. What hormonal changes occur during the perimenopause? When a woman cycles, she produces two major hormones, Estrogen and Progesterone. Both of these hormones come from the cells surrounding the eggs. Estrogen is needed for the uterine lining to grow and Progesterone is produced when the egg is released at ovulation.
    [Show full text]
  • Review Article Physiologic Course of Female Reproductive Function: a Molecular Look Into the Prologue of Life
    Hindawi Publishing Corporation Journal of Pregnancy Volume 2015, Article ID 715735, 21 pages http://dx.doi.org/10.1155/2015/715735 Review Article Physiologic Course of Female Reproductive Function: A Molecular Look into the Prologue of Life Joselyn Rojas, Mervin Chávez-Castillo, Luis Carlos Olivar, María Calvo, José Mejías, Milagros Rojas, Jessenia Morillo, and Valmore Bermúdez Endocrine-Metabolic Research Center, “Dr. Felix´ Gomez”,´ Faculty of Medicine, University of Zulia, Maracaibo 4004, Zulia, Venezuela Correspondence should be addressed to Joselyn Rojas; [email protected] Received 6 September 2015; Accepted 29 October 2015 Academic Editor: Sam Mesiano Copyright © 2015 Joselyn Rojas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The genetic, endocrine, and metabolic mechanisms underlying female reproduction are numerous and sophisticated, displaying complex functional evolution throughout a woman’s lifetime. This vital course may be systematized in three subsequent stages: prenatal development of ovaries and germ cells up until in utero arrest of follicular growth and the ensuing interim suspension of gonadal function; onset of reproductive maturity through puberty, with reinitiation of both gonadal and adrenal activity; and adult functionality of the ovarian cycle which permits ovulation, a key event in female fertility, and dictates concurrent modifications in the endometrium and other ovarian hormone-sensitive tissues. Indeed, the ultimate goal of this physiologic progression is to achieve ovulation and offer an adequate environment for the installation of gestation, the consummation of female fertility. Strict regulation of these processes is important, as disruptions at any point in this evolution may equate a myriad of endocrine- metabolic disturbances for women and adverse consequences on offspring both during pregnancy and postpartum.
    [Show full text]
  • Association Between Increased Expression of Endothelial Isoform of Nitric Oxide Synthase in the Human Fallopian Tube and Tubal Ectopic Pregnancy
    Iran J Reprod Med Vol. 12. No. 1. pp: 19-28, January 2014 Original article Association between increased expression of endothelial isoform of nitric oxide synthase in the human fallopian tube and tubal ectopic pregnancy Leyla Fath Bayati1 M.Sc., Marefat Ghaffari Novin1, 2 M.D., Ph.D., Fatemeh Fadaei Fathabadi1 Ph.D., Abbas Piryaei1 Ph.D., Mohammad Hasan Heidari1 Ph.D., Mozhgan Bandehpour2 Ph.D., Mohsen Norouzian1 Ph.D., Mahdi Alizadeh Parhizgar3 M.D., Mahmood Shakooriyan Fard3 B.Sc. 1. Department of Biology and Abstract Anatomical Sciences, Faculty of Medicine, Shahid Beheshti Background: Tubal ectopic pregnancy (tEP) is the most common type of extra- University of Medical Sciences, uterine pregnancy and the most common cause of maternal mortality. Nitric oxide Tehran, Iran. (NO) is a molecule that incorporates in many physiological processes of female 2. Cellular and Molecular Biology reproductive system. Recent studies have demonstrated the possible role of Research Center, Shahid Beheshti University of Medical endothelial isoform of nitric oxide synthase (eNOS) enzyme in the regulation of Sciences, Tehran, Iran. many reproductive events that occur in the fallopian tube (FT). 3. Department of Pathology, Objective: The aim of this study was to evaluate the expression of eNOS in the FTs Kamkar Arab-Niya Hospital, of women with tEP. Qom University of Medical Sciences, Qom, Iran. Materials and Methods: In this case-control study, a total number of 30FTs samples were obtained from three groups including: 10 FTs of women that bearing an EP, 10 FTs from the non-pregnant women at luteal phase of the menstrual cycle, and 10 FTs of healthy pregnant women (n=10).
    [Show full text]